Topoisomerase 1 Inhibitor

Camptothecin Drug-Linker

Builds on a mechanism with a proven track record in solid tumors.

Zymeworks camptothecin payload is specifically designed for antibody-drug conjugate (ADC) use and is paired with established linker and conjugation technologies that provide a good balance of stability, safety, and anti-tumor activity.

How It Works

Zymeworks Topoisomerase-1 inhibitor technology uses a novel fit-for-purpose camptothecin payload with moderate potency and strong bystander activity in conjunction with a traceless, plasma-stable, cleavable peptide linker. The properties of the drug-linker enable conjugation at a drug to antibody ratio up to 8. Catabolism of the ADC following target engagement, internalization, and lysosomal trafficking releases the topoisomerase inhibitor payload ZD06519.

 

How We Differ

We keep the ADC in mind, from concept to pipeline application.

Our lead payload was developed specifically for ADCs, with selection driven by four key elements:

  1. Moderate potency
  2. Strong bystander activity
  3. Limited hydrophobicity
  4. Favorable absorption, distribution, metabolism and excretion (ADME) characteristics.